Literature DB >> 22649035

Negative predictive value for cancer in patients with "gray-zone" PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 Tesla MR.

Rossano Girometti1, Massimo Bazzocchi, Giuseppe Como, Giovanni Brondani, Matteo Del Pin, Bruno Frea, Guillermo Martinez, Chiara Zuiani.   

Abstract

PURPOSE: To investigate the negative predictive value (NPV) for malignancy of 3.0 Tesla (T) MRI in patients with "gray zone" PSA level and prior negative biopsies.
MATERIALS AND METHODS: We enrolled 26 patients with PSA level between 2.5 and 10 ng/mL and no cancer at previous biopsies. Examinations were performed on a 3.0T system using T2-weighted imaging, diffusion-weighted imaging, spectroscopy, and postcontrast dynamic study. A regional scheme was used to record MRI findings and to perform subsequent transrectal-ultrasonography-guided biopsy. Based on the matching between imaging and biopsy findings we estimated MRI predictive values, sensitivity, specificity and accuracy on a per-patient and per-region basis.
RESULTS: On a per patient basis, MRI had five true-positive (5/26; 19.2%), eight true-negative (8/26; 30.8%) and no false-negative cases, corresponding to a NPV and sensitivity of 100% each. Thirteen patients were assessed as false-positive cases (13/26; 50.0%) (specificity of 38.1%). Five of them (5/26; 19.2%) showed high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small-acinar proliferation (ASAP) at biopsy. T2-weighted imaging alone showed per-region NPV (96.8%).
CONCLUSION: Because of the high NPV, MRI had the potential to avoid unnecessary biopsy in approximately one-third of "gray-zone" patients with a negative examination. Additionally, MRI was useful to address to biopsy more than one-third of patients with cancer or high-risk lesions as HGPIN and ASAP.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22649035     DOI: 10.1002/jmri.23703

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.

Authors:  Nabeel A Shakir; Arvin K George; M Minhaj Siddiqui; Jason T Rothwax; Soroush Rais-Bahrami; Lambros Stamatakis; Daniel Su; Chinonyerem Okoro; Dima Raskolnikov; Annerleim Walton-Diaz; Richard Simon; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2014-08-09       Impact factor: 7.450

Review 2.  The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Authors:  Chen Jie; Liu Rongbo; Tan Ping
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

3.  Microarray-based identification of individual HERV loci expression: application to biomarker discovery in prostate cancer.

Authors:  Philippe Pérot; Valérie Cheynet; Myriam Decaussin-Petrucci; Guy Oriol; Nathalie Mugnier; Claire Rodriguez-Lafrasse; Alain Ruffion; François Mallet
Journal:  J Vis Exp       Date:  2013-11-02       Impact factor: 1.355

Review 4.  Multi-parametric MRI imaging of the prostate-implications for focal therapy.

Authors:  James S Wysock; Herbert Lepor
Journal:  Transl Androl Urol       Date:  2017-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.